Evidence
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
Front Nutr. 2023 May 18;10:1163950. doi: 10.3389/fnut.2023.1163950. eCollection 2023.
ABSTRACT
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the most common form of liver disease. Curcumin is a natural polyphenol that may be effective against liver steatosis and steatohepatitis. The present study aimed to evaluate the effects of phytosomal curcumin on lipid profile, fasting blood sugar, anthropometric indices, liver enzymes, fibrosis, and steatosis in non-alcoholic fatty liver patients.
METHODS: The participants were randomized to the curcumin-phosphatidylserine phytosomal receiving group and the placebo receiving group and were followed up for 12 weeks. Data on anthropometric indices, lipid profile, blood glucose, blood pressure, liver enzymes, hepatic steatosis, and fibrosis were collected at the beginning and the end of the clinical trial.
RESULTS: Supplementation for 12 weeks with phytosomal curcumin significantly reduced fibrosis and steatosis in the phytosomal curcumin receiving group compared with the placebo group (p < 0.05). Phytosomal curcumin also significantly reduced waist circumference and blood pressure compared with the placebo group (p < 0.05). There was no significant difference between the phytosomal curcumin and the placebo groups regarding changes in weight, body mass index, fasting blood glucose, liver enzymes, and lipid profile.
CONCLUSION: Curcumin, at a dose of 250 mg per day, might be effective in treating patients with NAFLD. Further studies are necessary to confirm these findings and to discover the underlying mechanisms.
CLINICAL TRIAL REGISTRATION: https://www.irct.ir/trial/43730, identifier: IRCT20121216011763N39.
PMID:37275651 | PMC:PMC10233031 | DOI:10.3389/fnut.2023.1163950
![Google](https://www.google.com/images/branding/googlelogo/2x/googlelogo_light_color_92x30dp.png)
![Google Keep](https://www.gstatic.com/images/branding/product/1x/keep_48dp.png)
![Share on Linkedin](https://psychiatryai.com/wp-content/uploads/2023/10/linkedin-logo-png-2048-1.png)
Estimated reading time: 4 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
![](/wp-content/uploads/2024/04/bd462cc11bcf0bd0d0d6f1d0f8b7cd04-modified-1.png)
Cool Evidence: Engaging Young People and Students in Real-World Evidence
![](/wp-content/uploads/2024/04/bd462cc11bcf0bd0d0d6f1d0f8b7cd04-modified-1.png)
Real-Time Evidence Search [Psychiatry]
![](/wp-content/uploads/2024/04/pubmed.png)
AI Research
![](/wp-content/uploads/2024/05/Il5nR_nf_400x400-modified-1.png)
The effect of curcumin on anthropometric indices, blood pressure, lipid profiles, fasting blood glucose, liver enzymes, fibrosis, and steatosis in non-alcoholic fatty livers
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
The effects of replacing ghee with rapeseed oil on liver steatosis and enzymes, lipid profile, insulin resistance, and anthropometric measurements in patients with non-alcoholic fatty liver disease: A randomized controlled clinical trial The Influence of Emodin Succinyl Ethyl Ester on Non-Alcoholic Steatohepatitis Induced by a Diet High in Fructose, Cholesterol, and Fat in Mice Impact of Flaxseed Supplementation on Lipid Profile and Liver Enzymes in Patients with Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis of Randomized Controlled Trials Impact of Flaxseed Supplementation on Lipid Profile and Liver Enzymes in Patients with Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis of Randomized Controlled Trials Relationship between changes in blood glucose, glycosylated hemoglobin [HbA1c], cholesterol, and triglyceride and changes in hepatic enzymes Tartaric acid ameliorates experimental non-alcoholic fatty liver disease by activating the AMP-activated protein kinase signaling pathway Tartaric acid ameliorates experimental non-alcoholic fatty liver disease by activating the AMP-activated protein kinase signaling pathway Blood Level of Nitric Oxide Metabolites and Expression of Genes Regulating NO Synthesis in Early Forms of Non-Alcoholic Fatty Liver Disease Blood Level of Nitric Oxide Metabolites and Expression of Genes Regulating NO Synthesis in Early Forms of Non-Alcoholic Fatty Liver Disease The effects of grape seed extract supplementation on cardiovascular risk factors, liver enzymes and hepatic steatosis in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study MiR-18 regulates lipid metabolism of non-alcoholic fatty liver disease via IGF1 Targeting Non-Alcoholic Fatty Liver Disease with Hawthorn Ethanol Extract (HEE): A Comprehensive Examination of Hepatic Lipid Reduction and Gut Microbiota Modulation Liver Lipidomics Analysis Revealed the Protective mechanism of Zuogui Jiangtang Qinggan Formula in type 2 diabetes mellitus with non-alcoholic fatty liver disease Liver Lipidomics Analysis Revealed the Protective mechanism of Zuogui Jiangtang Qinggan Formula in type 2 diabetes mellitus with non-alcoholic fatty liver disease 4,4-Diallyl curcumin bis(2,2-hydroxymethyl)propanoate ameliorates nonalcoholic steatohepatitis in methionine-choline-deficient diet and Western diet mouse models Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob/ob mice From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial Comparison of size of the liver between patients with non-alcoholic fatty liver disease and healthy controls Review article: Hepatic steatosis and its associations with acute and chronic liver diseases 3D microscaffolds with triple-marker sensitive nanoprobes for studying fatty liver disease in vitro Temporal relationship between hepatic steatosis and blood pressure elevation and the mediation effect in the development of cardiovascular disease The effect of soy isoflavones supplementation on metabolic status in patients with non-alcoholic fatty liver disease: a randomized placebo controlled clinical trial The effect of soy isoflavones supplementation on metabolic status in patients with non-alcoholic fatty liver disease: a randomized placebo controlled clinical trial Role of Angiotensin II in Non-Alcoholic Steatosis Development A Review: Cytochrome P450 in Alcoholic and Non-Alcoholic Fatty Liver Disease Probiotic supplementation for 24 weeks in patients with non-alcoholic steatohepatitis: the PROBILIVER randomized clinical trial Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease Genetic correlations between liver fat content, metabolic health, and adiposity distribution in the Fels Longitudinal Study Effect of Zuogui Jiangtang Qinggan Formula on lipid metabolism in db/db mouse model of type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease Role of prostaglandin E2 and its receptors in chronic liver disease Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step? Comparative and Predictive Significance of Serum Leptin Levels in Non-alcoholic Fatty Liver Disease Regulatory pathways and therapeutic potential of PDE4 in liver pathophysiology Cardiometabolic and Metabolic Profiles of Lean/Normal, Overweight and Obese Patients with Nonalcoholic Fatty Liver Disease EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) Significance of serum ferritin and De Ritis ratio in non-alcoholic fatty liver disease as diagnostic markers The protective effects of Ninjin'yoeito against liver steatosis/fibrosis in a non-alcoholic steatohepatitis model mouse Non-alcoholic Fatty Liver Disease Among Iraqi Patients With Psoriasis: A Case-Control Study Non-alcoholic Fatty Liver Disease Among Iraqi Patients With Psoriasis: A Case-Control Study Effects of Ganjianglingzhu Decoction on Lean Non-Alcoholic Fatty Liver Disease in Mice Based on Untargeted Metabolomics Role of FXR in the development of NAFLD and intervention strategies of small molecules The Regulatory Mechanism of Smilax China L. Saponins against Nonalcoholic Fatty Liver Is Revealed by Metabolomics and Transcriptomics The association between healthy eating index-2015 with anthropometric, cardiometabolic and hepatic indices among patients with non-alcoholic fatty liver disease The gut-liver axis in fatty liver disease: role played by natural products Hepatic steatosis, metabolic dysfunction and risk of mortality: findings from a multinational prospective cohort study Hepatic steatosis, metabolic dysfunction and risk of mortality: findings from a multinational prospective cohort study Metabolic dysfunction-associated fatty liver disease and low muscle strength: A comment Novel blood and tissue-based mitochondrial D-loop mutations detected in an Iranian NAFLD patient cohort Multiscale 3D genome organization underlies duck fatty liver with no adipose inflammation or serious injury Evaluating the relative importance of different blood pressure indices in screening for NAFLD: a survey report based on a health examination population Emerging roles of RNA-binding proteins in fatty liver disease Triglyceride Glucose Index is Associated with Ultrasonographic Fatty Liver Indicator in Children and Adolescents with Non-alcoholic Fatty Liver Disease Beneficial Effects of Capybara Oil Supplementation on Steatosis and Liver Apoptosis in Obese Mice Effects of the Pituitary-targeted Gland Axes on Hepatic Lipid Homeostasis in Endocrine-associated Fatty Liver Disease-A Concept Worth Revisiting The effects of gut microbiome manipulation on glycemic indices in patients with non-alcoholic fatty liver disease: a comprehensive umbrella review Semaglutide alters gut microbiota and improves NAFLD in db/db mice Navigating the Link Between Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis and Cardiometabolic Syndrome Androsin alleviates non-alcoholic fatty liver disease by activating autophagy and attenuating de novo lipogenesis Association of Histopathological and Biochemical Aspects of NAFLD With the Severity of Liver Fibrosis in Individuals With Obesity: Cross-sectional Study Non-alcoholic fatty liver disease changes the expression and activity of hepatic drug-metabolizing enzymes and transporters in rats Spleen volume is independently associated with non-alcoholic fatty liver disease, liver volume and liver fibrosis Mitochondrial ACSS1-K635 acetylation knock-in mice exhibit altered metabolism, cell senescence, and nonalcoholic fatty liver disease Serum Vitamin D Level in Overweight Individuals and Its Correlation With the Incidence of Non-alcoholic Fatty Liver Disease
Evidence Blueprint
The effect of curcumin on anthropometric indices, blood pressure, lipid profiles, fasting blood glucose, liver enzymes, fibrosis, and steatosis in non-alcoholic fatty livers
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
The effect of curcumin on anthropometric indices, blood pressure, lipid profiles, fasting blood glucose, liver enzymes, fibrosis, and steatosis in non-alcoholic fatty livers
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
The effects of replacing ghee with rapeseed oil on liver steatosis and enzymes, lipid profile, insulin resistance, and anthropometric measurements in patients with non-alcoholic fatty liver disease: A randomized controlled clinical trial Effects of curcumin/turmeric supplementation on the liver enzymes, lipid profiles, glycemic index, and anthropometric indices in non-alcoholic fatty liver patients: An umbrella meta-analysis Effect of nano-micelle curcumin on hepatic enzymes: A new treatment approach for non-alcoholic fatty liver disease (NAFLD) Exenatide and Metformin Improve Serum Indices and Intestinal Flora in patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease Curcumin protects against high-fat diet-induced non-alcoholic simple fatty liver by inhibiting intestinal and hepatic NPC1L1 expression via down-regulation of SREBP-2/HNF1α pathway in hamsters Curcumin protects against bisphenol A-induced hepatic steatosis by inhibiting cholesterol absorption and synthesis in CD-1 mice The Influence of Emodin Succinyl Ethyl Ester on Non-Alcoholic Steatohepatitis Induced by a Diet High in Fructose, Cholesterol, and Fat in Mice A Hospital Based Observational Study to Detect Non-Alcoholic Steatohepatitis by Acoustic Radiation Force Impulse in Individuals with Diabetes Mellitus and Metabolic Syndrome Effect of Intermittent Fasting on Lipid Profile, Anthropometric and Hepatic Markers in Non-Alcoholic Fatty Liver Disease (NAFLD): A Systematic Review Impact of Flaxseed Supplementation on Lipid Profile and Liver Enzymes in Patients with Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis of Randomized Controlled Trials Impact of Flaxseed Supplementation on Lipid Profile and Liver Enzymes in Patients with Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis of Randomized Controlled Trials Relationship between changes in blood glucose, glycosylated hemoglobin [HbA1c], cholesterol, and triglyceride and changes in hepatic enzymes Curcumin effects on glycaemic indices, lipid profile, blood pressure, inflammatory markers and anthropometric measurements of non-alcoholic fatty liver disease patients: A systematic review and meta-analysis of randomized clinical trials The effect of DASH diet on atherogenic indices, pro-oxidant-antioxidant balance, and liver steatosis in obese adults with non-alcoholic fatty liver disease: A double-blind controlled randomized clinical trial Pomegranate (Punica granatum L.) peel extract ameliorates metabolic syndrome risk factors in patients with non-alcoholic fatty liver disease: a randomized double-blind clinical trial Various types of fasting diet and possible benefits in nonalcoholic fatty liver: Mechanism of actions and literature update Tartaric acid ameliorates experimental non-alcoholic fatty liver disease by activating the AMP-activated protein kinase signaling pathway Tartaric acid ameliorates experimental non-alcoholic fatty liver disease by activating the AMP-activated protein kinase signaling pathway Association of neck circumference-related indices with metabolic, atherogenic and liver function biomarkers in patients with non-alcoholic fatty liver disease: a cross-sectional study Risk factors for macro vascular disease in type 2 diabetes mellitus patients with non-alcoholic fatty liver disease Effect of Cornus mas L. fruit extract on blood pressure, anthropometric and body composition indices in patients with non-alcoholic fatty liver disease: A double-blind randomized controlled trial Metabolic study of iron deposition based on magnetic resonance in patients with nonalcoholic fatty liver disease Compromised very-low density lipoprotein induced polyunsaturated triglyceride accumulation in N-nitrosodiethylamine-induced hepatic steatosis Effects of intermittent fasting regimens on glycemic, hepatic, anthropometric, and clinical markers in patients with non-alcoholic fatty liver disease: Systematic review and meta-analysis of randomized controlled trials Protective Effects of Curcumin Against Alcoholic Fatty Liver Why do some glucose-lowering agents improve non-alcoholic fatty liver disease whereas others do not? A narrative review in search of a unifying hypothesis Protective role of curcumin in disease progression from non-alcoholic fatty liver disease to hepatocellular carcinoma: a meta-analysis Blood Level of Nitric Oxide Metabolites and Expression of Genes Regulating NO Synthesis in Early Forms of Non-Alcoholic Fatty Liver Disease Blood Level of Nitric Oxide Metabolites and Expression of Genes Regulating NO Synthesis in Early Forms of Non-Alcoholic Fatty Liver Disease The effects of grape seed extract supplementation on cardiovascular risk factors, liver enzymes and hepatic steatosis in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study MiR-18 regulates lipid metabolism of non-alcoholic fatty liver disease via IGF1 Analysis of clinical features and identification of risk factors in patients with non-alcoholic fatty liver disease based on FibroTouch Targeting Non-Alcoholic Fatty Liver Disease with Hawthorn Ethanol Extract (HEE): A Comprehensive Examination of Hepatic Lipid Reduction and Gut Microbiota Modulation Diagnostic Performance of Quantitative Ultrasound Parameters in Non-alcoholic Fatty Liver Disease Liver Lipidomics Analysis Revealed the Protective mechanism of Zuogui Jiangtang Qinggan Formula in type 2 diabetes mellitus with non-alcoholic fatty liver disease Liver Lipidomics Analysis Revealed the Protective mechanism of Zuogui Jiangtang Qinggan Formula in type 2 diabetes mellitus with non-alcoholic fatty liver disease 4,4-Diallyl curcumin bis(2,2-hydroxymethyl)propanoate ameliorates nonalcoholic steatohepatitis in methionine-choline-deficient diet and Western diet mouse models Targeted platelet with hydrogen peroxide responsive behavior for non-alcoholic steatohepatitis detection Correlation of Grades of Non-alcoholic Fatty Liver on Ultrasound With Blood Parameters What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver? What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver? AN1284 attenuates steatosis, lipogenesis, and fibrosis in mice with pre-existing non-alcoholic steatohepatitis and directly affects aryl hydrocarbon receptor in a hepatic cell line Corrected and republished from: Metabolic associated liver disease Synergistic effect rescue animal model from NASH caused by diet-inflammation inducer Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob/ob mice Resmetirom: An Orally Administered, Smallmolecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis Role of microRNA in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a comprehensive review Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases Unmasking the enigma of lipid metabolism in metabolic dysfunction-associated steatotic liver disease: from mechanism to the clinic Long-term and liver-selected ginsenoside C-K nanoparticles retard NAFLD progression by restoring lipid homeostasis Research progress of celastrol on the prevention and treatment of metabolic associated fatty liver disease Non-alcoholic fatty liver disease and periodontal disease: A systematic review and meta-analysis of cross-sectional studies Vitamin K2 protects mice against non-alcoholic fatty liver disease induced by high-fat diet Effects of coenzyme Q10 supplementation on lipid profiles and liver enzymes of nonalcoholic fatty liver disease (NAFLD) patients: A systematic review and meta-analysis of randomized controlled trials Fructose Aggravates Copper-deficiency-induced Non-alcoholic Fatty Liver Disease Anti-Angiogenic Effects of Natural Compounds in Diet-Associated Hepatic Inflammation From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences Medium- and long-chain triglyceride propofol activates PI3K/AKT pathway and inhibits non-alcoholic fatty liver disease by inhibiting lipid accumulation Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial Puerarin protects the fatty liver from ischemia-reperfusion injury by regulating the PI3K/AKT signaling pathway Comparison of size of the liver between patients with non-alcoholic fatty liver disease and healthy controls Review article: Hepatic steatosis and its associations with acute and chronic liver diseases Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease A review of experimental and clinical studies on the therapeutic effects of pomegranate (Punica granatum) on non-alcoholic fatty liver disease: Focus on oxidative stress and inflammation